



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Anticipated Classification

This Application:

Class \_\_\_\_\_ Subclass \_\_\_\_\_

Prior Application:

Exam'r: Gary L. Kunz, Ph.D.

Group Art Unit: 1803

Attorney's

Docket No.:

Enz-47 (C2)

**FILED BY EXPRESS MAIL**

Hon. Commissioner of Patents and Trademarks

Washington, D.C. 20231

**BOX FWC (if under \$1.62)**

Sir:

This is a request for filing a X CONTINUATION    DIVISIONAL  
   CONTINUATION-IN-PART application under X 37 CFR §1.60  
   37 CFR §1.62, of pending prior application Serial No. 07/446,235  
filed on December 4, 1989 of Christine L. Brakel et al.  
Inventor(s)

for:

**MODIFIED NUCLEOTIDE COMPOUNDS**

Title of Invention

1.    Enclosed is a copy of the prior application, as originally filed and an affidavit or declaration verifying it as a true copy.
2.    A copy of the verified statement under 37 CFR §1.9 and §1.27 establishing small entity status in the prior application is also enclosed. Small entity status is still applicable.
3. X The filing fee is calculated as follows:


CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT								
					RATE			FEE
	Number Filed		Number Extra		Small Entity	Other Entity		Small Entity Other Entity
Total Claims	1	=	0	x	\$ 11	\$22	=	\$ -- \$0
Independent Claims	1	=	0	x	\$ 38	\$76	=	\$ -- \$0
Multiple Dependent Claims Presented: <u>  </u> Yes <u>X</u> No					\$115	\$230		\$ --- \$
If 117 reference in Col. 1 of 1999 then zero, enter "0" in Col.2					BASIC FEE			\$0
								\$ 365
					TOTAL FEE			\$0
								\$635

07/23/1997  
01 FC:202  
02 FC:203  
03 FC:204

OWNER: 00000089, DAI: 051135  
If 117 reference in Col. 1 of 1999 then zero, enter "0" in Col.2  
385.00 CH  
125.00 CH

**Attorney's Docket No. Enz-47(C2)**

C:\wpwin\ENZ.47C2\rgstfor.con

<b>EXPRESS MAIL CERTIFICATE</b>	
"Express Mail" Label No. <u>TB842440643</u>	
Deposit Date <u>JUNE 7, 1995</u>	
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231	
 Ronald C. Fedus - Reg. No. 32,567	<u>JUNE 7, 1995</u> Date

Page: 2 (Request for a Continuation Application Under 37 C.F.R. § 1.60 - June 7, 1995)

D'

14. \_\_\_\_\_ A preliminary amendment is enclosed.

Page: 3 (Request for a Continuation Application Under 37 C.F.R. § 1.60 - June 7, 1995)

- Ronald C. Fedus, Esq.  
Enzo Therapeutics, Inc.  
c/o Enzo Biochem, Inc.  
575 Fifth Avenue (18th Floor)  
New York, New York 10017

- The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

C:\wpwin\ENZ\_47\G2\rastler.com

Brakel et al.

Serial No.: Not Yet Assigned


Filed: Herewith

Page: 4 (Request for a Continuation Application Under 37 C.F.R. § 1.60 -  
June 7, 1995)

Code and that such willful false statements may jeopardize the validity of the  
application or any patent issuing thereon.

June 7, 1995

Date



Signature [Ronald C. Fedus]

1. Registration No. 32,567

Attorney for Applicants

           Inventor(s)

           Assignee of Complete Interest

  X   Attorney or Agent of Record

           Filed under 37 CFR §1.34(a)

Address of Signator:

Enzo Therapeutics, Inc.

c/o Enzo Biochem, Inc.

575 Fifth Avenue (18th Floor)

New York, New York 10017

Attorney's Docket No. Enz-47(C2)